Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose:
The pathophysiology of Fibromyalgia Syndrome (FMS) is incompletely understood. An imbalance of pro- and anti-inflammatory cytokines is assumed to play a role in the induction and maintenance of pain, but the many studies that have investigated cytokine levels in patients with FMS presented diverse results. The objective of our study was to analyze different cytokines, oxidative stress markers and brain-derived neurotrophic factor (BDNF) in patients with FMS. Considering that depression is also a possible cause of alteration in some of these markers, its presence was analyzed.
Methods:
A total of 130 female subjects (69 FMS and 61 healthy controls) were included in the present study. The cytokines (IL-6, IL-10 and TNFα), oxidative stress markers (Thiobarbituric Acid Reactive Substances – TBARS – and carbonyl) and BDNF expression patterns were evaluated in all subjects. The Hamilton and Beck`s depression scales, as well as the Fibromyalgia Impact Questionnaire (FIQ), were applied in FMS patients. BDNF serum levels were measured by sandwich-ELISA; the concentration of serum cytokines was determined by flow cytometry; levels of lipid peroxidation were measured by the method of TBARS and oxidative damage to proteins were analyzed by the determination of carbonyl groups content in proteins.
Results:
Age was similar between groups (44.5 ± 6.4 years in FMS and 44.0 ± 6.7 in controls; p= 0.613). In the FMS group, the mean of FIQ was 70.3 ± 18.1 and almost all patients had depression (95.6 %) considering an abnormal score on specific scales. The majority of patients had mild/moderate depression (52.2% on Beck scale and 66.6% on Hamilton scale). IL-10 levels where significantly higher in FMS subjects, but other cytokines and biomarkers did not differ between the groups. (table). There was no correlation of any biomarker or cytokine with the FIQ and the Hamilton and Beck`s depression scales.
Comparison of oxidative stress markers, BDNF and cytokines in FMS patients and healthy controls
|
|
FMS patients (n=69 ) |
Healthy controls (n=61) |
p value* |
|
|
median (IQR) |
median (IQR) |
|
|
Neuropsychiatric biomarkers |
|
|
|
|
TBARS (µM of MDA) |
13.2 (9.8, 20.5) |
14.4 (8.7, 29.2) |
0.808 |
|
BDNF (ng/mL) |
30.8 (21.8, 37.1) |
30.7 (21.1, 35.4) |
0.595 |
|
Carbonil (nmol/mg) |
0.019 (0.015, 0.022) |
0.021 (0.015, 0.027) |
0.132 |
|
Cytokines (fg/mL) |
|
|
|
|
IL-6 |
1498.7 (743.5, 2595.6) |
1077.1 (720.0, 2119.1) |
0.128 |
|
IL-10 |
593.5 (348.4, 890.2) |
441.4 (266.6, 569.8) |
0.006 |
|
TNF-α |
187.3 (145.7, 670.3) |
187.3 (76.1, 352.9) |
0.255 |
*Mann-Whitney test; the p value is not adjusted for multiple comparisons. IQR: interquartile range
Conclusion:
The significant increase of serum IL-10 in patients with FMS found in this study may indicate a disregulation of antiinflammatory cytokines in this disease. This finding was also seen in patients with chronic fatigue syndrome, disease that is also characterized for chronic pain and tiredness.
Disclosure:
A. Ranzolin,
None;
C. A. D. C. Neto,
None;
B. M. Ascoli,
None;
B. Wollenhaupt-Aguiar,
None;
A. L. B. P. Duarte,
None;
M. Bredemeier,
None;
F. Kapczinski,
None;
R. M. Xavier,
Pfizer, Roche and Merck,
5.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytokines-oxidative-stress-markers-and-brain-derived-neurotrophic-factor-in-fibromyalgia-syndrome/